Melton Biomedical International Co., Limited is a technology-driven enterprise specializing in the development and application of gene delivery vector technologies, headquartered in Hong Kong.
Melton's core technology lies in its F gene Defective-Sendai Virus (SeV) Vector, a cutting-edge gene delivery system. Sendai virus serves as an ideal gene delivery platform due to its strong safety profile (cytoplasmic expression), high infectivity (MOI=3), low immunogenicity (achieved through F gene deletion and temperature-sensitive mutations), and large gene-loading capacity.
Currently, Melton has developed an iPSC Reprogramming Kit based on the F-defective SeV technology. Additionally, Melton offers other SeV-derived products, such as the Cell Fusion Kit HVJ-E. The company is actively establishing GMP-compliant production systems to deliver clinical-grade products and customized technical services, including SeV-based collaborative development of anti-infective vaccines, oncolytic viruses, and CAR-T therapies.
（Melton is headquartered in the Qianhai Excellent Financial Center (Phase I), Shenzhen City, China）
(Melton recombinant Sendai virus vector research and development in BSL-2 laboratory)
Melton's VisionMelton is committed to leveraging its innovative products and technologies to contribute to global public health advancements.
